HERANTIS PHARMA OYJ

HERANTIS PHARMA OYJ

Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. Its products in pipeline includes Cerebral Dopamine Neurotrophic Factor (CDNF), which is in Phase 1-2 clinical trial for the treatment of Parkinson's disease; xCDNF, an engineered derivative to treat neurodegenerative diseases; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer related lymphedema. The company was founded in 2008 and is based in Espoo, Finland.

Herantis Pharma Oyj_logo

Industry:
Company

Founded:
6/17/2008

Address:
Bertel Jungin Aukio 1, Espoo, Finland Zipcode 02600

Country:
Finland

Phone:
358 9222 1195

Market Cap:
26.73M
Total Assets:
16.42M
Total Cash:
12.34M

CEO: Craig Cook (Since 2020)


Key Executives
Name Title Pay Year Born
Dr. Craig Richard Cook Chief Exec. Officer N/A 1967(53 years old)
Ms. Tone Kvale Chief Financial Officer N/A 1969(51 years old)
Dr. Antti Vuolanto Chief Operating Officer N/A N/A
Dr. Henri J. Huttunen Chief Scientific Officer N/A N/A
Ms. Sigrid Booms Head of Regulatory Affairs & Compliance N/A N/A
Ms. Jutta Poutanen MSc Chief Pharmaceutical Officer N/A N/A
Mr. Jani Koskinen Head of Quality & CMC Devel. N/A N/A
Dr. Magnus Sjoegren M.D., Ph.D. Chief Medical Officer N/A N/A
Ms. Outi Lahdenperä M.D., Ph.D. Chief Medical Ofcer N/A N/A



Financial & Stock
Exchange Helsinki. Currency in EUR. Market state REGULAR
According to Herantis Pharma Oyj's financial reports the company's revenue in 2020 were 0 an decrease(NAN%) over the years 2019 revenue that were of 0. In 2020 the company's total earnings were -9.15M while total earnings in 2019 were -8M( +12.5%).
Company's stock symbol is HRTIS.HE. Lastest price : 2.7400. Total volume :703.00 Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.herantis.com

  • Host name: fi-p2.seravo.net
  • IP address: 95.217.73.113
  • Location: Finland
  • Latitude: 60.1717
  • Longitude: 24.9349
  • Timezone: Europe/Helsinki

Loading ...
Loading ...


More informations about "Herantis Pharma Oyj" on Search Engine

Herantis Pharma - Innovative therapies for better lives

Herantis.com Herantis Pharma is a publicly listed drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs.

Herantis Pharma - Innovative therapies for better lives

Herantis.com Herantis Pharma is a publicly listed (HRTIS and HRNTS) drug development company …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Based on internationally recognized science, Herantis’ drug development pipeline targets …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Overview and contact us. Our vision at Herantis is to produce innovative …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Investors. Herantis is a public company listed on Nasdaq First North Growth Market …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Turku Offices Herantis Pharma Plc. Pharmacity, Itäinen Pitkäkatu 4 B FI-20520 …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Tel: +358 9 222 1195 Email: info (at) herantis.com VAT number FI21986657

Herantis Pharma - Innovative therapies for better lives

Herantis.com I have read the privacy notice of Herantis Pharma Plc and give my consent to the …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Herantis Pharma Plc Half year financial report 1 January – 30 June 2017 [PDF] March 17 …

Herantis Pharma - Innovative therapies for better lives

Herantis.com CDNF is a protein naturally present in humans. It was discovered by Professor Mart …

Herantis Pharma - Innovative therapies for better lives

Herantis.com Tel: +358 9 222 1195 Email: info (at) herantis.com VAT number FI21986657

Herantis Pharma - Parempi elämä innovatiivisilla

Herantis.com Herantis Pharma pitää esitelmän ja posteriesityksen CDNF:n ensimmäisestä kliinisestä tutkimuksesta AD/PD™ virtuaalisessa konferenssissa Lue lisää Osakkeenomistajien nimitystoimikunnan ehdotukset Herantis Pharma Oyj:n varsinaiselle yhtiökokoukselle 2021

Herantis Pharma Oyj (HRTIS.HE) Company Profile & Facts

Finance.yahoo.com Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine.

HRTIS:FN Finland Stock Quote - Herantis Pharma Oyj

Bloomberg.com About Herantis Pharma Oyj Herantis Pharma PLC manufactures pharmaceutical products. The Company develops drugs to treat various types of diseases. Herantis Pharma serves …

Herantis Pharma - Herantis Pharma Oyj : Managers

Herantis.com Dec 18, 2020 · Company release 18 Dec 2020 at 4:00pm EET Herantis Pharma Oyj – Managers’ Transactions _____ Person subject to the notification requirement Name: Kvåle, Tone Position: Chief Financial Officer Issuer: Herantis Pharma Plc LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20201218145324_2 …

Herantis Pharma - Herantis Pharma Oyj : Managers

Herantis.com _____ Person subject to the notification requirement Name: Heiman, Mats Position: Closely associated person (1): Person Discharging Managerial Responsibilities In Issuer Name: Atteryd Heiman, Ingrid Position: Member of the Board Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: …

Herantis Pharma Announces R&D Update - Herantis Pharma Oyj

News.cision.com Herantis Pharma Announces R&D Update Sun, Nov 01, 2020 21:00 CET. Herantis Pharma Plc (“Herantis”), an innovative drug development company aiming to revolutionize standard therapeutic approaches with leading biologic and gene therapy, today announced an update on its Research & Development pipeline.

Herantis Pharma osallistuu Nordic Life Science Days

News.cision.com 2 hours ago · Herantis Pharma Oyj, Yhtiötiedote, 13.4.2021, klo 8:00 Herantis Pharma Oyj (“Herantis”) , lääkekehitysyhtiö, joka keskittyy hermorappeumasairauksien taudinkulkuun vaikuttavien hoitojen kehitt ä miseen, ilmoitti tänään että sen toimitusjohtaja Craig Cook pitää digitaalisen yhtiöesittelyn ja osallistuu kahdenkeskisiin tapaamisiin ...

Herantis Pharma Oyj (HRTIS.HE) Stock Price, News, Quote

Finance.yahoo.com Herantis Pharma Plc ("Herantis" or "Company") announced today that patient recruitment in the Company's Phase 2 clinical trial AdeLE ("Adenoviral gene therapy for the treatment of …

KUTSU HERANTIS PHARMA OYJ:N VARSINAISEEN …

News.cision.com Herantis Pharma Oyj Herantis Pharma Oyj on innovatiivinen lääkekehitysyhtiö, joka pyrkii tuomaan lääkekehitykseen perinteisestä poikkeavia lähestymistapoja hoitojen uudistamiseksi. Herantiksen …

Herantis Pharma Oyj: Herantis Pharma to focus on CDNF and

Arvopaperi.fi Mar 30, 2021 · Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii.

Herantis Pharma Oyj - Herantis Pharma Oyj - Cision

News.cision.com Herantis Pharma Oyj Wed, Mar 03, 2021 07:00 CET. Low resolution. Medium resolution. Original resolution. About Us. Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the ...

Herantis Pharma - Herantis Pharma Oyj: Manager’s

Herantis.com May 31, 2019 · Herantis Pharma Oyj: Manager’s Transactions - James Phillips Herantis Pharma Plc Company release 31 May 2019 at 1:00 pm Herantis Pharma Oyj - Managers' Transactions _____ Person subject to the notification requirement Name: Phillips, James Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification …

Herantis Pharma Oyj : to focus on CDNF and xCDNF programs

Marketscreener.com Herantis Pharma Plc. Company release, Inside Information . 29 March 2021 at 9:00 PM EET. Herantis Pharma Plc ("Herantis or the Company"), an innovative clinical stage biotech company pioneering new disease modifying and regenerative therapies, today announced that the Board of Directors has decided to focus all company resources on Herantis' CDNF and xCDNF assets and to commence seeking out ...

Herantis Pharma Oyj : Announces R&D Update | MarketScreener

Marketscreener.com Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii.

Herantis Pharma Oyj : Plc launches an accelerated

Marketscreener.com Herantis Pharma Oyj : Plc launches an accelerated bookbuilding process to raise a minimum of EUR 6.5 million through a private placement of new shares. 12/17/2020 | 12:22pm EDT *: *: * THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR ...

Herantis Pharma Oyj : NOTICE TO CONVENE HERANTIS PHARMA

Marketscreener.com Herantis Pharma Plc. Company release 23 March 2021 at 19:10 p.m. EET. Notice is given to the shareholders of Herantis Pharma Plc to the Annual General Meeting of the Company to be held on 15 April 2021, commencing at 10.00 a.m. (Eastern European Summer Time) at the premises of Krogerus Attorneys Ltd, at the address Unioninkatu 22, 00130 Helsinki, Finland.

Herantis Pharma Oyj (HLSE:HRTIS) - Share price, News

Simplywall.st Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics.

Herantis Pharma Oyj: NOTICE TO CONVENE HERANTIS PHARMA …

Arvopaperi.fi Mar 24, 2021 · Herantis Pharma Plc. Company release 23 March 2021 at 19:10 p.m. EET. Notice is given to the shareholders of Herantis Pharma Plc to the Annual General Meeting of the Company to be held on 15 April 2021, commencing at 10.00 a.m. (Eastern European Summer Time) at the premises of Krogerus Attorneys Ltd, at the address Unioninkatu 22, 00130 Helsinki, Finland.

Herantis Pharma and Nanoform Enter into Agreement for

News.cision.com Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that they have entered into a Biologics Proof of Concept Agreement with Nanoform Finland Plc, an innovative nanoparticle medicine enabling company. The collaboration ...

Herantis Pharma keskittyy CDNF- ja xCDNF-ohjelmiin

News.cision.com Herantis Pharma Oyj (“Herantis” tai “Yhtiö”), innovatiivinen kliinisen vaiheen lääkekehitysyhtiö, joka kehittää uusia sairauden kulkuun vaikuttavia regeneratiivisia hoitoja, tiedotti tänään yhtiön hallituksen päättäneen keskittää Herantiksen resurssit yhtiön CDNF- ja xCDNF-ohjelmiin ja aloittaa lisensointikumppanin ...

Herantis Pharma Oyj, HRTIS:HEX profile - FT.com

Markets.ft.com Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and...

Herantis Pharma Oyj: Herantis Pharma Published the Annual

Arvopaperi.fi Mar 25, 2021 · Herantis Pharma Plc. Company Press Release, 25 March 2021 at 08:00 a.m. EET. Herantis Pharma Plc ("Herantis"), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, has today published the annual report for 2020.

Herantis Pharma on julkaissut vuoden 2020 vuosikertomuksen

News.cision.com Herantis Pharma on julkaissut vuoden 2020 vuosikertomuksen to, maalis 25, 2021 07.00 CET. Herantis Pharma Oyj. Yhtiötiedote 25.3.2021 klo 08:00 . Herantis Pharma Oyj (“Herantis”), innovatiivinen lääkekehitysyhtiö, joka kehittää biologisiin lääkkeisiin ja geeniterapiaan perustuvia hoitoja, on tänään julkaissut vuoden 2020 vuosikertomuksen.. Vuosikertomus sisältää ...

HERANTIS PHARMA OYJ (HRPMF) Stock Price, News, Quote

Finance.yahoo.com Find the latest HERANTIS PHARMA OYJ (HRPMF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Herantis Pharma Oyj - Cision

News.cision.com Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation ...

Herantis Pharma Oyj, HRTIS:HEX summary - FT.com

Markets.ft.com Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging rese arch about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis ...

Herantis Pharma Oyj : Plc launches a directed offering of

Marketscreener.com Herantis Pharma Plc Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER …

Herantis Pharma Oyj: Herantis Pharma Full Year Report 2020

Arvopaperi.fi Mar 03, 2021 · Herantis Pharma Plc Company Release 3 March 2021 at 8:00 a.m. EET Press Release. Herantis Pharma Plc ("Herantis"), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today published its Full Year Report for January - December 2020.

Herantis Pharma Oyj - Company Profile and News - Bloomberg

Bloomberg.com Company profile page for Herantis Pharma Oyj including stock price, company news, press releases, executives, board members, and contact information

Herantis Pharma Oyj: Herantis Announces Inconclusive

Arvopaperi.fi Herantis Pharma Plc. Company release, inside information, 2 March 2021 at 2:00 p.m. Eastern European Time. Herantis Pharma Plc ("Herantis"), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that clinical trial results from its Phase II study investigating Herantis' patented gene therapy Lymfactin®, …

Herantis Pharma Full Year Report 2020 - ipohub.io

Ipohub.io Herantis Pharma Oyj . Herantis Pharma PLC is a pharmaceutical drug development company. It focused on developing regenerative medicine for unmet clinical needs. The products of the group are CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, CDNF for Amyotrophic lateral sclerosis and CDNF for other neurodegenerative diseases. The ...

HERANTIS PHARMA OYJ : Stock Market News and Information

Marketscreener.com HERANTIS PHARMA OYJ : News, information and stories for HERANTIS PHARMA OYJ | NASDAQ OMX HELSINKI LTD.: HRTIS | NASDAQ OMX HELSINKI LTD.

HRPMF Stock Price | Herantis Pharma Oyj Stock Quote (U.S)

Marketwatch.com Herantis Pharma Oyj. Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. It offers medicinal products such …

HERANTIS PHARMA OYJ : Shareholders Board Members Managers

Marketscreener.com Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis ...

HRPMF | Herantis Pharma Oyj Profile | MarketWatch

Marketwatch.com Herantis Pharma Oyj. Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. It offers medicinal products such …

Herantis Pharma Oyj (HRTIS.OL) Stock Price, News, Quote

Finance.yahoo.com Find the latest Herantis Pharma Oyj (HRTIS.OL) stock quote, history, news and other vital information to help you with your stock trading and investing.

HRPMF | Herantis Pharma Oyj Stock Price & News - WSJ

Wsj.com View the latest Herantis Pharma Oyj (HRPMF) stock price, news, historical charts, analyst ratings and financial information from WSJ.

HRTIS.HE - Herantis Pharma Oyj Profile | Reuters

Reuters.com Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and ...

HRPMF: Herantis Pharma Oyj - Stock Price, Quote and News

Cnbc.com Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and ...

Herantis Pharma - Company and Press Releases

Herantis.com Herantis Pharma Announces an Oral Presentation and a Poster Presentation related to First-in-Man CDNF Clinical Trial at AD/PD™ Virtual Conference 09.03.2021 Proposals of the Shareholders’ Nomination Committee to Herantis Pharma Plc’s Annual General Meeting 2021

Herantis Pharma Oyj, HRNTS:STO summary - FT.com

Markets.ft.com Latest Herantis Pharma Oyj (HRNTS:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.

Herantis Pharma OYJ (HRPMF) Stock Quotes | Nasdaq

Nasdaq.com Herantis Pharma OYJ (HRPMF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Herantis Pharma Oyj | Yrityksen tiedot - Taloussanomat

Is.fi Yritys: Herantis Pharma Oyj, Helsinki - Katso yhteystiedot, taloustiedot sekä uutiset maksutta Taloussanomien yritystietopalvelusta.

Herantis Pharma Oyj (HRTIS) osake - Nordnet

Nordnet.fi Herantis Pharma Oyj: Herantis Pharma to focus on CDNF and xCDNF programs; 25.3.2021 klo 7.00 · Cision Herantis Pharma Oyj: Herantis Pharma Published the Annual Report for the Financial Year 2020; 25.3.2021 klo 7.00 · Cision Herantis Pharma Oyj: Herantis Pharma on julkaissut vuoden 2020 vuosikertomuksen; 23.3.2021 klo 18.10 · Cision

0986786D Stock Quote - Herantis Pharma Oyj - Bloomberg Markets

Bloomberg.com Stock analysis for Herantis Pharma Oyj (0986786D) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Herantis Pharma OYJ (HRPMF) Financials | Nasdaq

Nasdaq.com Find the latest Financials data for Herantis Pharma OYJ (HRPMF) at Nasdaq.com.